Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: Impact on Hospitalizations and Health Care Resource Utilization in a Universal Health Care Setting
In a national cohort of pwCF, ETI was associated with substantial reductions in elective hospitalizations, elective outpatient contacts, duration of elective hospitalizations, pharmacy visits, and blood sampling appointments, sustained 2 years post-ETI initiation. These findings highlight the real-world effectiveness of ETI in the context of a universal health care system.
Authors
- Søren Jensen‐Fangel
- Espen Jimenez‐Solem (ORCID: https://orcid.org/0000-0002-3777-147X)
- Daniel Faurholt‐Jepsen (ORCID: https://orcid.org/0000-0001-8561-0155)
- Mikkel Zöllner Ankarfeldt (ORCID: https://orcid.org/0000-0001-7954-9255)
- Hans Kristian Pedersen (ORCID: https://orcid.org/0009-0005-7959-1548)
- Camilla Bjørn Jensen (ORCID: https://orcid.org/0000-0002-8224-4601)
- Tavs Qvist (ORCID: https://orcid.org/0000-0002-1725-5312)
- Joanna Wang (ORCID: https://orcid.org/0000-0003-1723-1342)
- Janne Petersen
- Tacjana Pressler
Institutions
- University of Copenhagen (DK)
- Frederiksberg Hospital (DK)
- Bispebjerg Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Pulmonary Therapy
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1007/s41030-025-00287-1
- Citations
- 1
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Vertex Pharmaceuticals